Clinical trials: Radiation, open to volunteers
Nasopharyngeal Cancinoma (NPC)
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
Re-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life.
- Trial name
- NCT07528183
- Testing
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Keratoconus
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
- Trial name
- NCT07629557
- Testing
- Riboflavin Ophthalmic Solutions, UV-A Irradiation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Prostate Cancer
MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days
The Proseven trial is a prospective interventional study that will evaluate the toxicity and efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated treatment of prostate cancer.
- Trial name
- Proseven (NCT04896801)
- Testing
- MR-guided RT
- Where
- Belgium
- Volunteers
- 132 people
- Sponsor
- Universitair Ziekenhuis Brussel
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Prostate Adenocarcinoma
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy.
- Trial name
- NCT06499870
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sean Sachdev
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Gastric Cancer (Diagnosis), Gastric Cancer (GC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07502027
- Testing
- Iparomlimab and Tuvonralimab (QL1706)
- Volunteers
- 55 people
- Sponsor
- Huazhong University of Science and Technology
Lymphedema of Face, Neoplasms
Manual Lymph Drainage for External Lymphedema
This study will evaluate the feasibility of a randomized controlled trial. The future randomized controlled trial will compare two groups following different intensities of manual lymphatic drainage for external head- and neck…
- Conditions
- Lymphedema of Face, Neoplasms, Radiotherapy Side Effect, Lymphedema Due to Radiation
- Trial name
- MLD-HN (NCT07215169)
- Testing
- HIT, LIT
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Lund University
Prostate Cancer
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy.
- Trial name
- NCT07291557
- Testing
- Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- AHS Cancer Control Alberta
Colon Cancer Liver Metastasis, Colon Cancer
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure.
- Conditions
- Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT04668872
- Testing
- Y90 TARE, PET/CT, PET/MRI
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Contouring, Segmentation
Locally Optimised Contouring With AI Technology for Radiotherapy
LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients.
- Conditions
- Contouring, Segmentation, Radiation Therapy, Artificial Intelligence
- Trial name
- LOCATOR (NCT06546592)
- Testing
- AI assisted contouring
- Where
- 3 sites in Australia
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- Royal North Shore Hospital
Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma
Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma
This study focuses on a common side effect experienced by many patients after radiation therapy for nasopharyngeal cancer, which is a type of head and neck cancer.
- Conditions
- Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma, Radiotherapy Side Effects, Radiotherapy Side Effect
- Trial name
- NCT07189572
- Testing
- Triamcinolone Acetonide
- Volunteers
- 168 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR)…
- Trial name
- ABCD RT (NCT07554573)
- Testing
- Radiation Therapy, Standard of Care Radiation Therapy, No Intervention
- Volunteers
- 5,270 people
- Sponsor
- NRG Oncology
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer of the Head and Neck, Oropharynx Cancer
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the…
- Conditions
- Cancer of the Head and Neck, Oropharynx Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Throat Carcinoma
- Trial name
- ENID (NCT04444869)
- Testing
- Cisplatin injection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Missouri-Columbia
Ototoxicity, Drug-Induced
Diagnostic of Various Ototoxicity Induced by Cancer Treatment
Visit the clinic once every 2 weeks for checkups and tests The goal of this clinical trial is to learn if systematic hearing tests (eg fonctional assesment, electrophysiology and seric biomarkers) can diagnose hidden hearing loss…
- Trial name
- BIO-OTOTOX (NCT06490029)
- Testing
- Auditory, vestibular and electrophysiological investigations, Biologic investigations; seric proteins
- Where
- France
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Cytokine-Induced Killer Cells, Advanced Milignant Gliomas
Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas.
- Trial name
- NCT02496988
- Testing
- Temozolomide, CIK
- Volunteers
- 120 people
- Sponsor
- The First People's Hospital of Changzhou
Breast Cancer
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast…
- Trial name
- NCT04517266
- Testing
- omit of IMI group, IMI group
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Ruijin Hospital
Metastatic Cancer
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (> 6 months) and displaying disease progression.
- Trial name
- RESTO-IMMUNO (NCT06363773)
- Testing
- Stereotactic Radiotherapy
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Elsan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.